This study investigated Kit receptor dysregulations (cytoplasmic immunohistochemical expression and/or c-KIT mutations) in cats affected with splenic mast cell tumours. Twenty-two cats were included. Median survival time was 780 days (range: 1-1219). An exclusive splenic involvement was significantly (P = 0.042) associated with longer survival (807 versus 120 days). Eighteen tumours (85.7%) showed Kit cytoplasmic expression (Kit pattern 2, 3). Mutation analysis was successful in 20 cases. Fourteen missense mutations were detected in 13 out of 20 tumours (65%). Eleven (78.6%) were located in exon 8, and three (21.6%) in exon 9. No mutations were detected in exons 11 and 17. Seven mutations corresponded to the same internal tandem duplication in exon 8 (c.1245_1256dup). Although the association between Kit cytoplasmic expression and mutations was significant, immunohistochemistry cannot be considered a surrogate marker for mutation analysis. No correlation was observed between c-Kit mutations and tumour differentiation, mitotic activity or survival.
Introduction
Visceral mast cell tumours (MCTs) are much more common in cats than in dogs, with over 50% of feline MCTs occurring in extracutaneous sites. Notably, splenic MCTs account for 15-26% of feline splenic disease and are the most common cause of neoplastic splenic disease in cats. 1, 2 Cats with splenic mast cell tumours (SMCTs) may have signs of systemic illness, including lethargy, anorexia, weight loss and intermittent vomiting. Palpation of the abdomen reveals massive splenomegaly in most of affected cats and, occasionally, peritoneal effusion. 2 -4 One third of cats with SMCT are anaemic, and up to 50% have evidence of bone marrow and peripheral blood involvement. 4, 5 Metastatic spread to the liver is also frequent. 2 The association of splenic and cutaneous disease has been increasingly reported, especially in cats presenting with multiple skin lesions, and in these cases, it is not clear which primary form of the tumour is more prevalent. 2, 6 Some authors have hypothesized an origin of feline visceral MCT from haematopoietic cell precursors, supporting a multicentre, 'liquid' growth. 7 Splenectomy is the treatment of choice, even in the presence of multi-organic disease, resulting in a median survival time of 19 months. 2, 6 The role of chemotherapy for the adjuvant treatment of feline MCT has not been clearly established. Similarly, there is no proven utility for corticosteroid administration.
with increased cellular proliferation and with both reduced progression-free and overall survival (OS). 10, 11 Consequently, Kit receptor tyrosine kinase inhibitors (TKIs) have entered as an active part of MCT treatment in dogs. 12, 13 Aberrant cytoplasmic Kit immunohistochemical expression has been reported in 29-67% of feline cutaneous MCTs, and a higher frequency was observed in tumours with unfavourable outcome.
14 -16 Furthermore, between 62 and 68% of feline cutaneous MCTs harbour c-KIT mutations in exons 8 and 9, and there are anecdotal reports of beneficial response to molecular targeted therapy. 17, 18 These findings suggest that TKIs may offer a new therapeutic option for selected cases of feline mast cell neoplasia. In a report by Dank et al. (2002) , no KIT mutations were identified in 10 cats with SMCT 19 ; however, exons 8 and 9 had not been investigated in that study and, since then, no specific research has been carried out to assess the true frequency of Kit receptor dysregulations in feline SMCTs. A better understanding of the role that Kit plays in the development of feline SMCTs may possibly provide help in the clinical approach and treatment of this disease.
This study aimed at characterizing Kit receptor dysregulations (i.e. cytoplasmic immunohistochemical expression and/or c-KIT mutations) in a series of feline SMCTs. Specifically, our goals were: (1) to assess whether aberrant cytoplasmic expression of Kit could be regarded as indicative of c-KIT mutations; and (2) to evaluate the relationship between Kit dysregulation and tumour morphology, proliferation and OS.
Materials and methods

Inclusion criteria and histological parameters
Formalin-fixed and paraffin-embedded (FFPE) surgical or post-mortem samples of feline SMCTs submitted to the diagnostic laboratories of the Department of Veterinary Medical Sciences (University of Bologna, Italy) and Laboratoire IDEXX (Saint Denis, France) for histopathological examination were considered for inclusion. Four micrometres histological sections stained with haematoxylin and eosin were reviewed by one pathologist (S. S.) and a metachromatic stain (toluidine blue) was applied in all cases to confirm the diagnosis and evaluate the amount of cytoplasmic granules. Table 1 summarizes the quantitative and qualitative histological parameters evaluated. The assessment of histopathological parameters was performed for each case on all the available tissue sections (range: 2-5). For the evaluation of the morphological type, the considered histopathological criteria were intercellular borders, nuclear-cytoplasmic ratio, nuclear morphology and the degree of pleomorphism.
Immunohistochemical analysis
Kit protein expression pattern was evaluated immunohistochemically. Tumour sections were immunolabelled using a commercial antihuman antibody (CD117, rabbit polyclonal, Dako, Glostrup, Denmark) with validated reactivity in feline tissues. 18, 20 Endogenous peroxidase activity was blocked by incubation for 30 min with 3% hydrogen peroxide in distilled water. For antigen retrieval, slides were microwaved in citrate buffer (pH 6.0), for two cycles of 5 min, at 750 W. Following incubation in a blocking solution (10% goat serum) for 30 min at room temperature, slides were incubated overnight at 4 ∘ C in a humid chamber with the primary antibody; CD117 was diluted 1:100 in phosphate-buffered saline.
Binding sites of primary antibody were identified using a secondary biotinylated antibody (1:200 in blocking solution, Dako) and an incubation step of 30 min at room temperature. Sections were then incubated with a commercial streptavidin-biotin-peroxidase kit (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA) and 3,3 ′ -diaminobenzidine (DAB tablets, Diagnostic BioSystems, Pleasanton, CA, USA) was used as chromogen. Sections were counterstained with Papanicolaou's haematoxylin, dehydrated and mounted.
A feline cutaneous MCT was used as positive control. Negative controls were obtained by omitting the primary antibody. Table 1 reports the methods for the evaluation of immunopositivity. 
Mutational status analysis
Genomic DNA was purified from 10 μm sections (three to five) of FFPE tumour samples by using a commercial kit (QIAmp DNA FFPE Tissue kit, Qiagen, Milan, Italy) and following manufacturer's instructions. The extracted DNA concentration and purity were measured using Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Waltham, MA, USA).
Exons 8, 9, 11 and 17 of feline KIT were amplified by polymerase chain reaction (PCR) as previously reported. 20 These exons represent KIT mutational hot spots and were chosen according to previously published reports on canine and feline MCTs and other Kit-dependent malignancies. 17,18,21 -30 PCR amplifications were carried out in a T-Personal thermocycler (Biometra GmbH, Göttingen, Germany) using 0.5 μM of each primer (Tema Ricerca, Castenaso, Italy), 0.5 μL of Phire Hot Start DNA Taq polymerase (Thermo Scientific), 200 μM deoxyribonucleotide triphosphate mix, 1× Phire buffer (final concentrations) and 80 ng of diluted DNA as template. The following PCR conditions were used: an activation step at 98 ∘ C for 45 s, 40 cycles of 15 s at 98 ∘ C, 20 s at 54 ∘ C (for full length exon 17), at 56 ∘ C (for full length exons 9, 11, 17) or 58 ∘ C (for full length exon 8 and shorter fragments of exons 8 and 9), 30 s at 72 ∘ C, and a final extension step of 2 min at 72 ∘ C. Amplicons were visualized in a 2% agarose gel electrophoresis. PCR products were sequenced on an automated sequencer by Macrogen Europe laboratories (Amsterdam, the Netherlands). Amplicons were sequenced starting from both forward and reverse primers used for the PCR amplification and from at least two different PCR products. The obtained electropherograms were analysed by FinchTV tool (Geospiza, Seattle, WA, USA) and Chromas Lite 2.01 (Technelysium Pty Ltd, South Brisbane, Australia). The alignment of the wild-type sequence, available in Ensembl Genome Browser database, with sequences obtained in this study was performed using Multalin interface page (http:// multalin.toulouse.inra.fr/multalin/).
Medical records
Patient records were reviewed to collect demographic information. Referring veterinarians and/ or owners were contacted for additional information, including history, clinical stage, laboratory findings, ultrasound/surgical findings, treatment details and outcome. Because of the retrospective nature of the study, the lack of medical data was not a criterion for exclusion.
Statistical analysis
When appropriate, data sets were tested for normality using the D' Agostino and Pearson omnibus normality test. Values were expressed either as mean ± standard deviation in case of normal distribution or as median with a range in case of non-normal distribution. The relationships among histological parameters and between histological parameters and Kit pattern were assessed by Fisher's exact test and analysis of variance. The same tests were applied to assess differences in age and sex distribution, presence of cutaneous involvement, morphological type (well-and moderately differentiated versus poorly differentiated), mitotic index (MI) and Kit pattern (membranous versus cytoplasmic) according to the mutational status. The impact of mutational status was assessed both considering all mutated cases together and grouping exon 8 internal tandem duplications (ITDs) separately. OS was defined as the time (days) from the date of diagnosis to the last reported date that the patient was seen alive. The patient status was recorded as alive, dead because of non-MCT-related causes or dead because of MCT-related causes. Univariate survival analysis (log-rank test) was carried out considering the following parameters: presence of extrasplenic involvement, therapy (surgery alone or surgery plus medical therapy), tumour differentiation, Kit pattern and mutational status.
Data were analysed using a commercial software programme (SPSS Statistics v 19, IBM); P values ≤0.05 were considered significant.
Results
Medical records
Twenty-two cats with a histologically confirmed SMCT were included in the study. There were 21 domestic shorthair and 1 domestic longhair. The age ranged from 6 to 16 years, with a mean of 11.6 ± 2.42 years. There were 8 males (36.4%) and 14 females (66.7%). Vomiting (n = 5; 22.7%), lack of appetite (n = 6; 27.3%) and the presence of a palpable abdominal mass (n = 12; 54.5%) were the most common clinical signs reported at presentation. Abdominal ultrasound and fine-needle liver aspirates were performed in all cases, whereas fine-needle aspiration of other abdominal organs was performed only in the presence of macroscopic alterations. Four patients had cytologically confirmed liver metastases. Buffy coat examination was performed in only five cats and mastocytemia was observed in two cases. Bone marrow cytology was performed in three cases, and two were positive for MCT infiltration. Two cats had also a single skin nodule at presentation and four later developed disseminated cutaneous MCTs. All cases of cutaneous involvement were confirmed either cytologically (n = 4) or histologically (n = 2).
One cat with massive neoplastic diffusion (involving spleen, liver, bone marrow and skin) was euthanized immediately following diagnosis and one cat only received corticosteroids. In both cases, histological samples of the spleen were obtained post-mortem. The remaining 20 cats underwent splenectomy: 12 were treated with splenectomy alone, 7 received adjuvant corticosteroids and one cat received adjuvant lomustine and a TKI (imatinib).
Follow-up information was available in 16 cases; including the 2 cats not receiving splenectomy (survival times, 10 and 60 days), 6 cats treated with splenectomy alone (median survival time, 120 days), 7 cats treated with splenectomy plus corticosteroids (median survival time, 480 days) and the cat receiving adjuvant chemotherapy (survival time, 400 days). Median survival time was overall 780 days (range: 1-1219). The presence of an exclusive splenic involvement (negative staging) was significantly (P = 0.042) associated with longer survival times (807 versus 120 days). There was no significant difference between cats treated with surgery alone or with surgery plus medical therapy.
Histological examination
In 18 cases (81.8%), the mastocytic infiltrate was diffuse, whereas 4 MCTs (18.2%) showed a lower cellularity and multifocal splenic infiltration. Eight tumours (36.4%) were classified as well-differentiated, and were composed by sheets of round to oval cells, 10-15 μm in diameter, with distinct cell borders. Cytoplasms were moderate to abundant, faintly granular, basophilic or pale eosinophilic. Nuclei were round to oval, with finely dispersed chromatin and inconspicuous nucleoli. The size of cells and nuclei within the neoplasm was rather uniform (variations < 50%). (Fig. 1) .
Nine tumours (40.9%) were classified as moderately differentiated and were characterized by sheets of cells, 15-20 μm in diameter, with mostly distinct cell borders and low amounts of eosinophilic cytoplasm. Nuclei were round or occasionally indented, with irregularly stippled chromatin and a small single central nucleolus visible in most cells. A variation of 50-100% in nuclear size was recorded (Fig. 1) .
Five tumours (22.7%), classified as poorly differentiated, were composed by polygonal cells, 15-20 μm in diameter, with mostly indistinct borders and scant, amphophilic cytoplasm. Nuclei were large, vesicular, often indented or bizarre, with prominent nucleoli. A variation of up to 100% in nuclear size was observed (Fig. 1) .
The MI ranged from 0 to 6 (mean, 2.2 ± 1.94). MI was significantly higher in moderately or poorly differentiated SMCTs (mean MI, 2.8) compared with well-differentiated SMCTs (mean MI, 1.1; P = 0.05).
Eosinophilic infiltrate was moderate to high in 2 cases (9.1%); in the remaining 20 cases (90.9%), eosinophils were low to absent. Necrosis was observed in four cases (18.2%).
Cytoplasmic granules were evaluated with toluidine blue stain and rated low in 3 cases (13.6%), moderate in 8 cases (36.4%) and high in 11 cases (50%). There was no statistical relationship among histological parameters or between histological parameters and survival.
Kit pattern
Twenty-one cases were immunoreactive for Kit protein. Three tumours (14.3%) revealed a prevalent membranous expression (Kit pattern 1), 11 (52.4%) had a focal cytoplasmic expression (Kit pattern 2) and 7 (33.3%) had a diffuse cytoplasmic expression (Kit pattern 3; Fig. 2 ). Of the cats with follow-up information, one had Kit pattern 1, eight had Kit pattern 2 and six had Kit pattern 3. There was no statistical relationship between Kit pattern and tumour differentiation, mitotic activity or survival.
Mutational status analysis
The c-KIT mutation status was investigated in all samples. In two cases (9.1%), the amplification was unsuccessful because of the poor quality of extracted DNA; thus, the following information refers to a total of 20 cases. No mutations were detected in exons 11 and 17; conversely, a number of sequence variants were observed in exons 8 and 9. Overall, fourteen missense mutations (resulting in Kit amino acid sequence alteration) were detected in 13 out of 20 tumours (65%). Eleven (78.6%) were located in exon 8, and 3 (21.4%) in exon 9; 1 tumour had two concurrent mutations in exons 8 and 9. The locations of the observed mutations are illustrated in Fig. 3 .
In particular, the mutations found in exon 8 consisted of three ITDs and one deletion-insertion.
Seven cases (35%) showed the same ITD, defined as c.1245_1256dup:p. 418T_419H ins QILT. This consists in the in frame duplication of 12 nucleotides (AATCCTGACTCA) in position 1245-1256 of KIT cDNA sequence, resulting in the insertion of QILT amino acids (Q, glutamine; I, isoleucine; L, leucine; T, threonine) between residues Thr418 and His419 of the Kit protein. Two further ITDs, namely c.1246_1257dup:p. 419H_420E ins ILTH and c.1247_1261dup:p. 420E_421S ins ILTHE, were observed in two and one cats, respectively. These ones correspond to a duplication of 12 (ATCCTGACTCAT) and 15 nucleotides (TCCT-GACTCATGAAA), and the insertion of four (ILTH) and five (ILTHE) amino acid residues (H, histidine; E, glutamic acid) between His419-Glu420 and Glu420-Ser421, respectively. The other identified mutation (c.1254_1263 delinsGTAA) is a 10 nucleotide (TCATGAAATC) deletion and a concomitant insertion of 4 nucleotides (GTAA), which results in the introduction of a premature stop codon. This last mutation was observed only in one cat (Fig. 3) .
In exon 9, only single nucleotide polymorphisms (SNPs) were observed: the missense mutation c.G1430T:p.S477I, occurring in two cases and c.C1426A:p.Q476K, occurring in one case (Fig. 3) . The silent mutations c.G1473A:p.E491E and c.G1479A:p.R493R were observed in further three cases.
c-Kit mutations were observed in 9 of the 16 cats with follow-up information (56.2%); 7 cases had an exon 8 ITD, 1 had an exon 8 delins mutation (c.1254_1263 delinsGTAA) and 1 displayed an exon 9 SNP (c.G1430T:p.S477I).
All the mutated tumours displayed an aberrant (focal or diffuse cytoplasmic) Kit pattern (P = 0.031), but a cytoplasmic expression was also observed in 4 out of 7 (57.1%) non-mutated tumours.
The mutational status was not apparently associated with tumour morphology, mitotic activity or survival time (Table 2) , not even considering exon 8 ITD mutations separately.
Discussion
This study confirms the tendency of feline SMCT to arise in aged patients; and the mean age of our feline population (12 years) is older than is usually reported for cutaneous MCTs (mean, 8-9 years). 18 The absence of a uniform staging protocol was one of the main limitations of this study, which may have affected the analysis of potentially prognostic factors.
If compared with dogs, staging procedures of feline MCT are far less standardized and their actual utility is still under debate. This is probably because of either the lower frequency of MCTs in cats or the fact that the biological behaviour of these tumours is considered less aggressive. Nevertheless, a subset of cats with cutaneous MCTs may also have asymptomatic splenic involvement, so, in the absence of an accurate staging, the extension of the disease may be underestimated. 4 Moreover, the presence of a disease limited to the spleen was the only factor significantly influencing survival in this study, suggesting that staging may be indicated for diagnostic purposes even in cats with a primary splenic presentation. Finally, cats with SMCT should be followed postoperatively with buffy coat smears, because a rise in the number of circulating mast cells may indicate disease progression. 2 At present, there are no available studies describing the histological features of feline SMCTs. The observation of our cases did not result in the identification of histological types similar to those reported in cutaneous MCTs. The evidence, in a limited number of cases of SMCTs, of a multifocal pattern, as opposed to the more frequent diffuse pattern, is more likely attributable to an early stage neoplastic infiltration. Nevertheless, we have identified different degrees of differentiation and, as previously observed in cutaneous and intestinal MCTs, a poor cell differentiation appears to match with a high mitotic activity, the only recognized histological prognostic factor in feline MCTs. 18, 20 Worth mentioning, in this study, the attribution of the degree of differentiation was based solely on the morphological appearance; the distribution and density of granules have been evaluated separately and were not correlated to the degree of differentiation. This is also confirmed by previous studies on feline cutaneous and intestinal MCTs. 18, 20 The primary goal of this study was to investigate the nature and incidence of Kit dysregulations in feline SMCTs. So far, c-KIT mutations have been detected with a frequency of 56% in cutaneous MCTs, whereas they have not been identified in intestinal MCTs. 18, 20 Although studies about the presence of mutations in feline MCTs with unspecified location have been previously published, 17 this is the first c-KIT mutation analysis specifically performed on a cohort of feline SMCT.
One possible limitation of this study is that samples for mutational analysis were FFPE. This can lead to an underestimation of the number of mutations because of the potential presence of either PCR inhibitors (solvents, paraffin) or of poor quality DNA (excessive fragmentation following formalin fixation). To improve the results of sequencing, for exons 8 and 9, we adopted the strategy of the amplification of shorter fragments. When unsuccessful, the phases of extraction and amplification were repeated several times and it was ultimately possible to define KIT mutational status in 20 out of 22 cases.
The identified mutations are very similar for frequency and type to those previously reported in feline cutaneous MCTs. 17, 18 All the mutations observed in this study were located within exons 8 and 9, which correspond to the fifth immunoglobulin-like domain (IgD5) of the Kit receptor. As in cutaneous MCTs, two hot spots were identified at the level of residues 415-421 (exon 8) and 476-477 (exon 9); nevertheless, while in cutaneous MCTs exon 9 mutations clearly prevailed, mutations in SMCT appear to occur more often in exon 8. In particular, the most frequent exon 8 mutation was the duplication c.1245_1256dup, consisting of the insertion of four amino acids (glutamine, isoleucine, leucine and threonine) between residues 418 and 419. Even though the ITD previously reported in feline MCT (AATCCTGACTCA) is one nucleotide shifted compared with the one observed in this study (AAATCCTGACTC), it results in the same protein sequence alteration. 17, 18, 31 These mutations were located in a neighbouring residue of mutations that have been reported in patients with paediatric mastocytosis and have been uncommonly described in canine MCT. 24, 32 Mutations at this level were considered to affect the affinity of the haemophilic dimerization of KIT, resulting in the constitutive activation of the kinase domain without ligand binding.
Missense mutations in exon 9 were also previously reported and they demonstrated to cause ligand-independent activation of KIT. 17, 33 Similar mutations have not been signalled in human tumours; however, identical substitutions were reported on the corresponding codon of Ser479 in canine MCT as an activating mutation. 24 In dogs, a good degree of correlation is observed between the presence of mutations and aberrant protein localization. Previous studies on feline cutaneous MCT failed to demonstrate a significant relationship between mutations and Kit pattern. 18 Although the association was significant in this study, we observed a very low incidence of the membranous pattern compared with the aberrant pattern also in non-mutated cases. This suggests that immunohistochemistry may describe a different kind of Kit dysregulation with respect to mutation analysis, and cannot be considered a reliable marker for mutations in feline MCTs.
As in previously published studies, we did not observe any significant correlation between mutations and survival time, mitotic activity or degree of differentiation; as a whole, this might be indicative of a secondary role of c-KIT mutations in affecting tumour biological behaviour. As a possible explanation, these mutations might simply reflect a genomic instability (passenger mutations), without providing any substantial advantage to the neoplastic population.
In conclusion, c-KIT mutations are present in more than 60% of feline SMCTs and are mostly represented by ITDs at the level of exon 8. However, their assessment for prognostic purposes appears to be of limited value in this species.
Potential limitations of this analysis are the relatively small number of cases, which may have resulted in the loss of statistical power, and its retrospective design, causing lack of uniformity in therapy protocols. The predictive role of Kit receptor remains to be investigated by evaluating the response to TKIs of feline SMCT in relation to the mutational status.
